Efficient Nose-to-Lung Aerosol Delivery with an Inline DPI Requiring Low Actuation Air Volume

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2018 Aug 23

PMID 30132207

Citations 19

Authors

Dale Farkas

Michael Hindle

P Worth Longest

Affiliations

Soon will be listed here.

Abstract

Purpose: To demonstrate efficient aerosol delivery through an in vitro nasal model using a dry powder inhaler (DPI) requiring low actuation air volumes (LV) applied during low-flow nasal cannula (LFNC) therapy.

Methods: A previously developed LV-DPI was connected to a LFNC system with 4 mm diameter tubing. System connections and the nasal cannula interface were replaced with streamlined components. To simulate nasal respiration, an in vitro nasal model was connected to a downstream lung simulator that produced either passive or deep nasal respiration. Performance of a commercial mesh nebulizer system was also considered.

Results: For the optimized system, steady state cannula emitted dose was 75% of the capsule loaded dose. With cyclic nasal breathing, delivery efficiency to the tracheal filter was 53-55% of the loaded dose, which was just under the design target of 60%. Compared with a commercially available mesh nebulizer, the optimal LV-DPI was 40-fold more efficient and 150 times faster in terms of delivering aerosol to the lungs.

Conclusions: The optimized LV-DPI system is capable of high efficiency lung delivery of powder aerosols through a challenging nasal cannula interface.

Citing Articles

Development of an Infant Air-Jet Dry Powder Aerosol Delivery System (iDP-ADS) Including a New Multifunctional Bifurcating Two-Prong Nasal Interface.

Strickler S, Farkas D, Momin M, Vargas L, Aladwani G, Hindle M Pharm Res. 2025; 42(2):365-384.

PMID: 39930310 PMC: 11880044. DOI: 10.1007/s11095-024-03814-y.

Characterization of Pediatric Extrathoracic Aerosol Deposition with Air-Jet Dry Powder Inhalers.

Thomas M, Bass K, Farkas D, Longest W J Aerosol Sci. 2025; 183.

PMID: 39830599 PMC: 11737425. DOI: 10.1016/j.jaerosci.2024.106474.

Development of CPAP Overlay Interfaces for Efficient Administration of Aerosol Surfactant Therapy to Preterm Infants.

Jubaer H, Strickler S, Farkas D, Dalton C, Momin M, Dodson K AAPS PharmSciTech. 2025; 26(1):34.

PMID: 39821052 DOI: 10.1208/s12249-024-02987-4.

Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) - Part I: In Vitro Testing and Characterization.

Momin M, Farkas D, Hindle M, Hall F, DiBlasi R, Longest W Pharm Res. 2024; 41(8):1703-1723.

PMID: 39112775 PMC: 11362531. DOI: 10.1007/s11095-024-03740-z.

Inhalable tobramycin EEG powder formulation for treating Pseudomonas aeruginosa-induced lung infection.

Pangeni R, Poudel S, Momin M, Farkas D, Dalton C, Hall F Int J Pharm. 2024; 662:124504.

PMID: 39053676 PMC: 11344668. DOI: 10.1016/j.ijpharm.2024.124504.

References

Longest P, Tian G, Hindle M . Improving the lung delivery of nasally administered aerosols during noninvasive ventilation-an application of enhanced condensational growth (ECG). J Aerosol Med Pulm Drug Deliv. 2011; 24(2):103-18. PMC: 3123840. DOI: 10.1089/jamp.2010.0849. View

Ward J . High-flow oxygen administration by nasal cannula for adult and perinatal patients. Respir Care. 2012; 58(1):98-122. DOI: 10.4187/respcare.01941. View

Behara S, Longest P, Farkas D, Hindle M . Development and comparison of new high-efficiency dry powder inhalers for carrier-free formulations. J Pharm Sci. 2013; 103(2):465-77. PMC: 3947484. DOI: 10.1002/jps.23775. View

Farkas D, Hindle M, Longest P . Development of an Inline Dry Powder Inhaler That Requires Low Air Volume. J Aerosol Med Pulm Drug Deliv. 2017; 31(4):255-265. PMC: 6067687. DOI: 10.1089/jamp.2017.1424. View

Hess D . The mask for noninvasive ventilation: principles of design and effects on aerosol delivery. J Aerosol Med. 2007; 20 Suppl 1:S85-98. DOI: 10.1089/jam.2007.0574. View

Kimbell J, Segal R, Asgharian B, Wong B, Schroeter J, Southall J . Characterization of deposition from nasal spray devices using a computational fluid dynamics model of the human nasal passages. J Aerosol Med. 2007; 20(1):59-74. DOI: 10.1089/jam.2006.0531. View

Tian G, Longest P, Li X, Hindle M . Targeting aerosol deposition to and within the lung airways using excipient enhanced growth. J Aerosol Med Pulm Drug Deliv. 2013; 26(5):248-65. PMC: 3826577. DOI: 10.1089/jamp.2012.0997. View

Sunbul F, Fink J, Harwood R, Sheard M, Zimmerman R, Ari A . Comparison of HFNC, bubble CPAP and SiPAP on aerosol delivery in neonates: An in-vitro study. Pediatr Pulmonol. 2014; 50(11):1099-106. DOI: 10.1002/ppul.23123. View

Golshahi L, Tian G, Azimi M, Son Y, Walenga R, Longest P . The use of condensational growth methods for efficient drug delivery to the lungs during noninvasive ventilation high flow therapy. Pharm Res. 2013; 30(11):2917-30. PMC: 3800269. DOI: 10.1007/s11095-013-1123-3. View

10.

Morley C, Bangham A, Miller N, Davis J . Dry artificial lung surfactant and its effect on very premature babies. Lancet. 1981; 1(8211):64-8. DOI: 10.1016/s0140-6736(81)90002-7. View

11.

Schroeter J, Kimbell J, Asgharian B . Analysis of particle deposition in the turbinate and olfactory regions using a human nasal computational fluid dynamics model. J Aerosol Med. 2006; 19(3):301-13. DOI: 10.1089/jam.2006.19.301. View

12.

Longest P, Golshahi L, Behara S, Tian G, Farkas D, Hindle M . Efficient Nose-to-Lung (N2L) Aerosol Delivery with a Dry Powder Inhaler. J Aerosol Med Pulm Drug Deliv. 2014; 28(3):189-201. PMC: 4559155. DOI: 10.1089/jamp.2014.1158. View

13.

Longest P, Azimi M, Golshahi L, Hindle M . Improving aerosol drug delivery during invasive mechanical ventilation with redesigned components. Respir Care. 2013; 59(5):686-98. DOI: 10.4187/respcare.02782. View

14.

Longest P, Hindle M . Numerical Model to Characterize the Size Increase of Combination Drug and Hygroscopic Excipient Nanoparticle Aerosols. Aerosol Sci Technol. 2011; 45(7):884-899. PMC: 3143486. DOI: 10.1080/02786826.2011.566592. View

15.

Farkas D, Hindle M, Longest P . Application of an inline dry powder inhaler to deliver high dose pharmaceutical aerosols during low flow nasal cannula therapy. Int J Pharm. 2018; 546(1-2):1-9. PMC: 7253153. DOI: 10.1016/j.ijpharm.2018.05.011. View

16.

Bhashyam A, Wolf M, Marcinkowski A, Saville A, Thomas K, Carcillo J . Aerosol delivery through nasal cannulas: an in vitro study. J Aerosol Med Pulm Drug Deliv. 2008; 21(2):181-8. DOI: 10.1089/jamp.2007.0662. View

17.

Longest P, Golshahi L, Hindle M . Improving pharmaceutical aerosol delivery during noninvasive ventilation: effects of streamlined components. Ann Biomed Eng. 2013; 41(6):1217-32. PMC: 3647043. DOI: 10.1007/s10439-013-0759-9. View

18.

Perry S, Kesser K, Geller D, Selhorst D, Rendle J, Hertzog J . Influences of cannula size and flow rate on aerosol drug delivery through the Vapotherm humidified high-flow nasal cannula system. Pediatr Crit Care Med. 2013; 14(5):e250-6. DOI: 10.1097/PCC.0b013e31828a7f79. View

19.

Tian G, Hindle M, Longest P . Targeted Lung Delivery of Nasally Administered Aerosols. Aerosol Sci Technol. 2014; 48(4):434-449. PMC: 4051279. DOI: 10.1080/02786826.2014.887829. View

20.

Son Y, Longest P, Hindle M . Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance. Int J Pharm. 2013; 443(1-2):137-45. PMC: 3584634. DOI: 10.1016/j.ijpharm.2013.01.003. View